Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma.

摘要: Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is almost never curable with current standard treatment consisting of surgical resection, irradiation and temozolomide. The prognosis remains poor despite undisputable advances understanding this tumor’s molecular biology pathophysiology, which unfortunately has so far failed to translate into a meaningful clinical benefit. Dysregulation resulting prominent pathophysiological role epidermal growth factor receptor (EGFR) have been identified several different malignant entities, GBM among them. EGFR overexpressed about 40% cases, half these coexpress mutant, constitutively activated subtype, EGFRvIII. Unfortunately, recent trials studying therapeutic approaches targeted against EGFRvIII meet expectations, only minority patients responding evidence good vitro rodent model activity. Having potentially high relevance within context, epithelial mesenchymal transition (EMT) phenomenon associated early stages carcinogenesis, cancer invasion recurrence. During EMT, cells lose many their characteristics, prominently E-cadherin expression, acquire properties that are typical for such as expression vimentin. Epithelial specifically demonstrated GBM. In review, we summarize EMT may precipitate resistance EGFR-targeted therapy, thus be principal factors contributing failure therapy